Skip to content

Author

Fu-Dong Shi

We have 4 of 39 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Nov 2026

Efficacy and safety of ofatumumab in Chinese participants with multiple sclerosis: results from a 12-month, prospective, open-label, multicenter study

Ofatumumab, a fully human anti-CD20 monoclonal antibody, has shown superior efficacy and a comparable overall safety profile to teriflunomide in the pivotal ASCLEPIOS I/II trials in people living with relapsing multiple sclerosis (plwRMS). However, data on the efficacy and safety of ofatumumab, a high-efficacy th...

Dong-Mei Jia, Hua-Bing Wang, Mei-Ni Zhang et al. · 0 citations
#federated learning Review Open access Oct 2026

Artificial intelligence in central nervous system autoimmune diseases: from clinical decision support to mechanistic discovery and translation

Central nervous system (CNS) autoimmune diseases, including multiple sclerosis (MS), neuromyelitis optica spectrum disorder (NMOSD), autoimmune encephalitis (AE), and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), remain difficult to diagnose, stratify, and treat because clinical phenotypes ov...

Zi-Jian Cao, Pei Zheng, Zhi-Hui Qi et al. · 0 citations
Aug 2026

Maternal NKG2D-mediated immune activation shapes fetal neural development.

It is demonstrated that MIA significantly increases the proportion of NK cells at the maternal-fetal interface, characterized by elevated expression of NKG2D, with this local accumulation persisting until late gestation, highlighting NK cell modulation as a potential therapeutic strategy for maternal infection-associat...

Rongrong Liu, Yuexin Zhao, Xianli Song et al. · 0 citations
Review Sep 2026

Recognition and management of acute relapse of multiple sclerosis, neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein antibody-associated disease.

The clinical patterns of acute attacks and relapses of multiple sclerosis, NMOSD and MOGAD are discussed, including the clinical and para-clinical modalities that are critical for timely recognition and diagnosis, and available evidence regarding treatment selection and responsiveness is presented.

Yu-Jing Li, Wei Jiang, Chao Zhang et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.